BNET Industries
Last Fiscal Year Sales:$647.3M
- Public
- US
Dow Jones Description
Abraxis Oncology is the proprietary pharmaceuticals division of Abraxis BioScience, LLC, an integrated global biopharmaceutical company. Abraxis Oncology is dedicated to the discovery and development of novel cancer therapies that target tumor biological pathways. Our focus is to challenge current standards and develop next-generation therapies that revolutionize the treatment of cancer. Through innovative science and creative thinking, Abraxis Oncology is redefining cancer therapy as we know it. It is our hope that the discovery of new technologies and new compounds will improve survival, as well as tolerability, across a range of tumor types.
Chief Executive Officer
Thomas H. SilbergNumber of Employees 1,375
Contact Information
1501 E Woodfield Rd Ste 300 E
Schaumburg, Illinois 60173-5837
(847) 969-2700
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Abraxane Gets Recalled in UK, Orphan Status in US
-
Abraxis BioScience Q3 Loss Widens - Update
-
Medicines sues generic drugmakers over Angiomax patent
-
BRIEF-APP Pharma gets approval for Deferoxamine Mesylate for injection, USP
-
Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...
-
CFOs on the Move: Week Ending July 17
-
Abraxis BioScience Names Mary Lynne Hedley, Ph.D., Executive Vice President of Operations and Chief Scientific...
-
Company and People Notes: Fresenius to Acquire APP Pharmaceuticals, Arete Therapeutics Appoints James Sabry President...
News & Analysis
Filter by
app pharmaceuticals inc. - All News and Analysis
Latest FDA Report Highlights: 8 Drugs That Carry Potential Risks
Mike Havrilla submits: The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber...
Best and Worst Performing Stocks of the Current Bear Market
Hickey and Walters Bespoke submit: Since the current bear market began back on October 9th, 2007, the Russell 1,000 is down about 18%. Of the stocks in the index, 8.5% are down more than 50%, while 25% are actually up since then. Below we highlight the 25 best...
APP Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Steven Hobb [ph] from Sierra Global Management. You may proceed. Steven Hobb – Sierra Global Management Yes, hi, thank you. I wondered what is the cost of debt at the moment and what is the...
Merger Watch: APP Pharmaceuticals - Fresenius
The M & A Researcher submits: APP Pharmaceuticals, Inc. APPX filed the definitive proxy statement for its merger with Fresenius with the SEC on Wednesday (August 20). There are no material updates to the pending HSR review process, nor any specific closing or target closing dates disclosed in...
APP Pharmaceuticals to Be Acquired by Fresenius
Combination Expands Leadership Position in Injectable Hospital Based Markets SCHAUMBURG, Ill. & BAD HOMBURG v.d.H., Germany -- APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading provider of hospital-based injectable pharmaceutical products, and Fresenius SE (XETRA:FRE), a global health care group with approximately $18 billion of sales in products and services for...
APP Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Hank Rauch with Liberty Mutual. Please proceed. Hank Rauch - Liberty Mutual Yeah. Thank you. I was wondering, I jumped on the call a little bit late, so if you already talked about this, I apologize....
Afternoon News You Can Use.
M2 PRESSWIRE-18 January 2008-Businessnewsnow.us: Afternoon News You Can UseC1994-2008 M2 COMMUNICATIONS LTD RDATE:17012008 New York, NY -- BusinessNewsNow's Stock News Highlights: AgFeed Industries, Inc. (NASDAQ: FEED); Hollund Industrial, Inc. (PINKSHEETS: HLLD); SM&A (NASDAQ: WINS); Greenstone Holdings,...
Morning News To Focus On For January 18, 2008.
M2 PRESSWIRE-18 January 2008-Businessnetwire.us: Morning News To Focus On For January 18, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:18012008 New York, NY -- BusinessNetWire's "Investor's Update" Focuses on the Following Companies: Avnet, Inc. (NYSE: AVT); Force Protection, Inc....
Speak with other shareholders about: (NASDAQ: FEED), (NASDAQ: WINS),. (PINKSHEETS: GSHN), (OTCBB: GORO), (Nasdaq: APPX).
M2 PRESSWIRE-18 January 2008-Stockwire.com: Speak with other shareholders about: (NASDAQ: FEED), (NASDAQ: WINS),. (PINKSHEETS: GSHN), (OTCBB: GORO), (Nasdaq: APPX)C1994-2008 M2 COMMUNICATIONS LTD RDATE:18012008 AUSTIN, TX -- Are you looking to speak with other investors about your favorite stock in...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Thomas H. Silberg | Chief Executive Officer |
| Derek J. Brown | Co-COO & Secretary |
| Frank Harmon | Chief Operating Officer |
| Jeffrey M. Yordon | Co-COO |
| John Weidenbruch | Chief Admin Officer, General Counsel & Secretary |
| Lisa Gopalakrishnan | Chief Financial Officer |
| Richard E. Maroun | Chief Admin Officer, General Counsel & Secretary |
| Richard J Tajak | Chief Financial Officer |
| Antonio Pera | Executive Vice President, Generic Business |
| Bruce J. Wendel | Executive Vice President, Corp Dev |
| Jack Silhavy | General Counsel, Vice President & Assistant Secretary |
| James W. Callanan | Vice President, Human Resources |
| Lorin Drake | Vice President |
| Mark R. Van Ausdal | General Counsel & Vice President |
| Mia Igyarto | Vice President, HR |
| Shahid Ahmed | Vice President |
| Thomas Shea | Vice President, Marketing |
| George Uy | Director, Marketing |
| Jackie Barnard | Senior National Reimbursement Manager |
| Mark Van | |
| Patrick Soon |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Patrick Soon-Shiong | Board Chairman |
| Alan L. Heller | Board of Directors |
| David S. Chen | Board of Directors |
| Kirk K. Calhoun | Board of Directors |
| Leonard Shapiro | Board of Directors |
| Michael Blaszyk | Board Director |
| Michael D. Blasyk | Board of Directors |
| Michael S Sitrick | Board of Directors |
| Sir Richard Sykes | Board Director |
| Stephen D. Nimer | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Chief Executive Officer | Current |
| American Pharmaceutical Products, Inc. | President and Chief Executive Officer | Current |
| Cobalis Corp | Board of Directors | Current |
| Tercica, Inc. | Chief Operating Officer | Former |
| Ligand Pharmaceuticals Incorporated | Coo | Former |
| APP Pharmaceuticals, Inc. | President, Abraxis Pharmaceutical Products & Executive Vice President, Commercial Operations | Former |
| Ligand Pharmaceuticals Incorporated | Executive Vice President | Former |
| Hoffmann-La Roche Inc. | Vice President of Business Operations | Former |
| University of Minnesota | BS | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Co-COO & Secretary | Current |
Mr. Harmon currently serves as executive vice president and chief operating officer for APP Pharmaceuticals. Prior to the spin-off of the proprietary business, Mr Harmon served as executive vice president and chief operating officer of Abraxis Pharmaceutical Products (APP) since September 2006, after having joined Abraxis in May 2006 as the executive vice president of global operations. Mr. Harmon oversees global manufacturing operations as well as the corporate quality assurance and quality control and the supply chain organizations as well as Generic Product Development, Regulatory Affairs and Operational Excellence. Prior to joining Abraxis, Mr. Harmon was the senior vice president, manufacturing operations for the Sterile Technologies Group at Cardinal Health where he was responsible for multiple sites throughout the United States and Puerto Rico. Mr. Harmon has also served as vice president, biopharmaceutical operations for Aventis Behring. Mr. Harmon earned an MBA from St. Louis University and undergraduate B.S. degrees in biology and chemistry from Western Kentucky University.
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Chief Operating Officer | Current |
| American Pharmaceutical Products, Inc. | Chief Operating Officer and Executive Vice President | Current |
| APP Pharmaceuticals, Inc. | Executive Vice President | Current |
| Abraxis | Executive Vice President | Former |
| Cardinal Health, Inc. | Senior Vice President, Manufacturing Operations | Former |
| Puerto Rico | Senior Vice President, Manufacturing Operations | Former |
| Saint Louis University | MBA | Former |
| Western Kentucky University | BS | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Co-COO | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Chief Admin Officer, General Counsel & Secretary | Current |
| Freehepatitisinfo | Executive Vice President and General Counsel | Current |
| APP Pharmaceuticals, Inc. | General Counsel & Assistant Crop Secretary | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Chief Financial Officer | Current |
| Intermix Media, Inc. | Chief Financial Officer | Former |
| APP Pharmaceuticals, Inc. | Executive Vice President | Former |
| Intermix Media, Inc. | Executive Vice President | Former |
| L.A. Gear, Inc. | Leadership Positions | Former |
| International Rectifier Corporation | Leadership Positions | Former |
| Organization | Position | Status |
|---|---|---|
| American Pharmaceutical Products, Inc. | Chief Administrative Officer, General Counsel and Corporate Secretary | Current |
| APP Pharmaceuticals, Inc. | Chief Admin Officer, General Counsel & Secretary | Current |
| APP Pharmaceuticals, Inc. | General Counsel | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| American Bioscience Inc. | Vice President | Former |
| Deloitte & Touche LLP | Senior Tax Manager | Former |
| American Bioscience Inc. | General Counsel | Former |
| Santa Clara University | Jd | Former |
| Boston University | Llm | Former |
| Santa Clara University | B.S. In Economics | Former |
| John Carroll University | B.S. In Economics | Former |
| Organization | Position | Status |
|---|---|---|
| American Pharmaceutical Products, Inc. | Executive Vice President and Chief Financial Officer | Current |
| APP Pharmaceuticals, Inc. | Chief Financial Officer | Current |
| APP Pharmaceuticals, Inc. | Executive Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Executive Vice President, Generic Business | Current |
| AmerisourceBergen Corporation | Senior Vice President, Supply Chain Management | Current |
| Ben Venue Laboratories Incorporated | Former | |
| DePaul University | M.B.A. | Former |
| University of Illinois | bachelor of science degree in business administration | Former |
| Organization | Position | Status |
|---|---|---|
| Abraxis Biosciences, Inc. | Executive. Vice President Corporate Development | Current |
| American Bioscience Inc. | Executive Vice President, Corporate Development | Current |
| APP Pharmaceuticals, Inc. | Executive Vice President, Corp Dev | Current |
| Bristol-Myers Squibb Company | Vice President, Corporate Development International Medicines | Former |
| APP Pharmaceuticals, Inc. | Vice President of Corporate Development | Former |
| IVAX Corporation | Vice President, Business Development | Former |
| Bristol-Myers Squibb Company | In, House Counsel | Former |
| SmithKline Beecham Corporation | Former | |
| Georgetown University | Juris Doctorate degree | Former |
| Georgetown Law School | Jd | Former |
| Cornell University | BS | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | General Counsel, Vice President & Assistant Secretary | Current |
Mr. Callanan currently serves as vice president, human resources for APP Pharmaceuticals. In his role at APP, Mr. Callanan is responsible for overseeing every aspect of human resources for APP including: human capital management, benefits, compensation design, environmental health and safety, training and organizational development. He is a member of the APP executive management team. Mr. Callanan's prior position was with ZLB Behring (formerly Aventis Behring) where he directed the human resources and training and organizational development functions for the 4,000 employee global biopharmaceutical manufacturing division, and had oversight for the company's plants throughout the U.S. and Europe. With more than 23 years experience in human resources, Mr. Callanan has held various HR leadership roles, both domestically and globally, at major pharmaceutical companies, including Fujisawa Healthcare Inc. and Sanofi. He received his Bachelor's degree in Business Administration from Indiana University.
| Organization | Position | Status |
|---|---|---|
| American Pharmaceutical Products, Inc. | Vice President, Human Resources | Current |
| APP Pharmaceuticals, Inc. | Vice President, Human Resources | Current |
| Indiana University | Bachelor's Degree In Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | General Counsel & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Vice President, HR | Current |
| Eastman Chemical Company | Former | |
| Kellogg School of Management at Northwestern University | M.B.A. | Former |
| Northwestern University | M.B.A. | Former |
| Northern Illinois University | B.S. in biology | Former |
| Northern Illinois University | B.S. in biology | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Vice President | Current |
| Akorn, Inc. | QC | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Vice President, Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Director, Marketing | Current |
| APP Pharmaceuticals, Inc. | Director, Marketing | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Senior National Reimbursement Manager | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Current | |
| American Bioscience Inc. | Director | Former |
| Organization | Position | Status |
|---|---|---|
| American College of Surgeons | Fellow | Current |
| APP Pharmaceuticals, Inc. | Board Chairman | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| American College of Surgeons | Fellow | Current |
| APP Pharmaceuticals, Inc. | CEO | Former |
| Abraxis Biosciences, Inc. | Chairman and Chief Executive Officer | Former |
| American Bioscience Inc. | President | Former |
| American Bioscience Inc. | Cfo | Former |
| APP Pharmaceuticals, Inc. | Board Director | Former |
| American Bioscience Inc. | Board Director | Former |
| University of British Columbia | M.Sc | Former |
| University of the Witwatersrand | Degree | Former |
Al has more than 30 years of leadership experience in a broad range of healthcare segments, with particular expertise in pharmaceuticals. He served as President and CEO of American Pharmaceutical Partners Inc. (APPI). Prior to APPI, Al worked with the Water Street team as an Operating Partner at One Equity Partners. Al also served as Senior Vice President and President of Global Renal Operations at Baxter. In this role, he led global operations for the Renal and Transfusion Therapies divisions, as well as global manufacturing and the office of the Chief Scientific Officer. Al began his career at G.D. Searle. During his 23 years with G.D. Searle, Al was promoted to numerous positions, including Co-President and Chief Operating Officer, and Executive Vice President and President of Searle Operations, a position in which he oversaw Searle's integration into Pharmacia. Al also served as a member of the Monsanto and Pharmacia Management Committees. He received his bachelor's degree from the University of Illinois, Chicago and his M.B.A from DePaul University.
| Organization | Position | Status |
|---|---|---|
| Water Street Healthcare Partners LLC | Operating Partner | Current |
| Applied Neurosolutions, Inc. | Director of the Company | Current |
| Applied Neurosolutions, Inc. | Board of Directors | Current |
| Multiple Myeloma | Board of Directors | Current |
| Iowabiotech.Com | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| Kalypsys, Inc. | Director | Current |
| Northfield Laboratories Inc. | Board of Directors | Current |
| The Multiple Myeloma Research Consortium Inc | Board of Directors | Current |
| Nfld | Board of Directors | Current |
| Savient Pharmaceuticals, Inc. | Director | Current |
| Baxter International Inc. | CEO | Former |
| APP Pharmaceuticals, Inc. | CEO | Former |
| APP Pharmaceuticals, Inc. | President | Former |
| Bank One Corp | Former | |
| JPMorgan Chase & Co. | Former | |
| Baxter International Inc. | Chairman | Former |
| DePaul University | M.B.A. | Former |
| University of Illinois at Chicago | Bachelor's Degree | Former |
| University of Illinois | Bs In Accounting | Former |
| University of Chicago | Bachelor of Science Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| California State University Long Beach | MBA | Former |
| National Taiwan University | BS | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular Systems, Inc. | Chairman | Current |
| Adams Respiratory Therapeutics, Inc. | Chairman | Current |
| Aspreva Pharmaceuticals Corporation | Chairman | Current |
| Adams Laboratories, Inc. | Board of Directors | Current |
| Response Genetics | Board of Directors | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| Ernst & Young | partner | Former |
| Cardiovascular Systems, Inc. | Board of Directors | Former |
| Adams Respiratory Therapeutics, Inc. | Board of Directors | Former |
| Aspreva Pharmaceuticals Corporation | Board of Directors | Former |
| University of Southern California | B.S. in Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Shapco, Inc. | Founder | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| Kelly Pipe Div. | President, Shapco | Former |
| Shapco, Inc. | CEO | Former |
| Shapco, Inc. | President | Former |
| Organization | Position | Status |
|---|---|---|
| Catholic Healthcare West, Inc. | Cfo | Current |
| Catholic Healthcare West, Inc. | Executive Vice President | Current |
| American Pharmaceutical Products, Inc. | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board Director | Current |
| University Hospitals Health System, Inc. | Cfo | Former |
| Boston Medical Center | Executive Vice President | Former |
| University Hospitals Health System, Inc. | Senior Vice President | Former |
| Community Hospitals | Senior Vice President | Former |
| Homecare, Inc. | Senior Vice President | Former |
| Boston University | Taught Health Care Finance and Economics | Former |
| University of Colorado | Masters Degree | Former |
| Wayne State University | Bachelors Degree | Former |
| University of Maryland | B.S. Degree In Business Administration and Journalism | Former |
| Organization | Position | Status |
|---|---|---|
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Sitrick & Co | CEO | Current |
| Sitrick & Co | Board Chairman | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Chairman and Chief Executive Officer, Sitrick and Company | Former |
| Sitrick & Co | Founder | Former |
| University of Michigan | Former |
| Organization | Position | Status |
|---|---|---|
| The Research and Development Society | President | Current |
| King's College London | Fellow | Current |
| Lonza Group Ltd. | Deputy Chairman | Current |
| Ukscf | Chairman | Current |
| Circassia Ltd | Non-Executive Chairman | Current |
| BioCeramic Therapeutics Ltd. | Chairman | Current |
| Combinature Biopharm AG | Chairman | Current |
| Rio Tinto plc | Chairman | Current |
| The Natural History Museum | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board Director | Current |
| Eurasian Natural Resources Corporation | Board of Directors | Current |
| Rio Tinto Limited | Board of Directors | Current |
| King's College | Fellow | Current |
| King's College London | Fellow | Current |
| The Royal Society | Fellow | Current |
| BioCeramic Therapeutics Ltd. | Rector | Former |
| Lincoln College | Fellow | Former |
| GlaxoSmithKline Plc | Chairman | Former |
| University of London | Doctor of Science Degree | Former |
| University of Madrid | Doctorate In Pharmacy | Former |
| University of Birmingham | Doctorate | Former |
Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Nimer is a member of many national professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the International Society for Stem Cell Research. He serves as a Reviewer for major medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association (JAMA) among many others. He serves on numerous national and international Grant Review Committees and is a prominent invited speaker at conferences on his areas of expertise. He has authored or co-authored nearly 200 peer-reviewed papers, reviews, editorials and textbook chapters, primarily focused on issues concerning hematology and oncology
| Organization | Position | Status |
|---|---|---|
| Memorial Sloan-Kettering Cancer Center Inc. | Chief of Hematology Service | Current |
| New England Journal of Medicine | Reviewer | Current |
| Memorial Hospital, Inc | Attending Physician | Current |
| The G&P Foundation for Cancer Research | Chairman | Current |
| Abraxis Biosciences, Inc. | Board of Directors | Current |
| American Society of Clinical Oncology | Board of Directors | Current |
| American Society of Hematology | Board of Directors | Current |
| Genpath | Board of Directors | Current |
| Neostem, Inc. | Board of Directors | Current |
| American Association for Cancer Research, Inc. | Board of Directors | Current |
| Onconova Therapeutics, Inc | Board of Directors | Current |
| APP Pharmaceuticals, Inc. | Board of Directors | Current |
| American Society of Hematology | Member | Current |
| American Association for Cancer Research, Inc. | Member | Current |
| American College of Physicians | Fellow | Current |
| Memorial Sloan-Kettering Cancer Center Inc. | Head | Former |
| University of California, Los Angeles | Former | |
| Cancer Research | Chairman | Former |
| University of Chicago | M.D. | Former |
| Massachusetts, Inc. | B.S. In Biology | Former |
| Massachusetts Institute of Technology | B.S. in Biology | Former |
| University of Chicago Pritzker School of Medicine | Degree | Former |
Executive News
-
APP Pharmaceuticals Receives Approval for Penicillin G Potassium for Injection, USP
-
APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
-
APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
-
Shamrock Activist Value Fund Files Preliminary Proxy Statement for Texas Industries, Inc. 2009 Annual Meeting
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Abraxis BioScience
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes

